🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "huge turning point" in the fight against drug-resistant strains of the bacteria, according to scientists.

An International Challenge

Gonorrhoea infections are on the rise around the world, with estimates suggesting in excess of 82 million instances per year. Particularly high rates are seen in the African continent and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary development in the context of growing infection rates, the spread of superbugs and the extremely scarce treatment choices at this time.”

Health officials are particularly alarmed about the increase in antibiotic-resistant strains. The World Health Organization has classified it as a "priority pathogen". Recent surveillance showed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Treatment Options Receive Authorization

Zoliflodacin, also known as a brand name, was cleared by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to significant complications, including the inability to conceive. Experts believe that specific application of this new drug will help delay the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This drug, which is also used to treat UTIs, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment emerged from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to develop it.

“This approval signifies a significant shift in the treatment of superbug gonorrhoea, which previously has been evolving faster than medical innovation.”

Research Study Outcomes and Worldwide Availability

According to findings published in a prominent scientific publication, the new drug eradicated more than 90% of cases of the STI. This places it at an comparable level with the existing first-line therapy, which uses an injection and a pill. The research enrolled nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the authority to license and sell the drug in a wide range of developing nations.

Clinicians directly involved have voiced optimism. Access to a easy-to-administer therapy such as this is hailed as a "critical tool" for managing the epidemic. This is considered essential to alleviate the strain of the illness for patients and to prevent the spread of extremely resistant gonorrhoea around the world.